Q1 Earnings Forecast for Ovid Therapeutics Issued By Wedbush

Ovid Therapeutics Inc. (NASDAQ:OVID) – Equities researchers at Wedbush lifted their Q1 2025 EPS estimates for Ovid Therapeutics in a note issued to investors on Wednesday, March 12th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($0.13) for the quarter, up from their previous forecast of ($0.15). Wedbush has a “Outperform” rating and a $3.00 price objective on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. Wedbush also issued estimates for Ovid Therapeutics’ Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.51) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.90) EPS and FY2028 earnings at $0.88 EPS.

A number of other brokerages have also recently weighed in on OVID. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Ovid Therapeutics in a research report on Wednesday, December 4th. Oppenheimer upgraded shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price target for the company in a research note on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $3.20.

Ovid Therapeutics Price Performance

Shares of OVID opened at $0.46 on Monday. Ovid Therapeutics has a 1-year low of $0.42 and a 1-year high of $3.45. The stock has a market cap of $32.72 million, a PE ratio of -0.98 and a beta of 0.29. The firm has a 50-day simple moving average of $0.63 and a two-hundred day simple moving average of $0.94. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.66 and a quick ratio of 5.66.

Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%. The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.19 million.

Institutional Trading of Ovid Therapeutics

Institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC lifted its position in shares of Ovid Therapeutics by 83.9% during the 4th quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock worth $35,000 after buying an additional 17,172 shares during the last quarter. XTX Topco Ltd increased its holdings in shares of Ovid Therapeutics by 46.2% in the 3rd quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock valued at $45,000 after acquiring an additional 12,076 shares during the period. FMR LLC increased its holdings in shares of Ovid Therapeutics by 1,907.4% in the 3rd quarter. FMR LLC now owns 50,225 shares of the company’s stock valued at $59,000 after acquiring an additional 47,723 shares during the period. Bank of America Corp DE increased its holdings in shares of Ovid Therapeutics by 49.7% in the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock valued at $53,000 after acquiring an additional 18,841 shares during the period. Finally, Velan Capital Investment Management LP acquired a new position in Ovid Therapeutics in the 4th quarter valued at $65,000. Hedge funds and other institutional investors own 72.24% of the company’s stock.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.